Risks
4 risks
Risk Intelligence
Delayed U.S. adalimumab market opening
View Risks →Biocon Limited — Q4 FY24
Biocon's Q4 FY24 group revenue from operations grew 4% YoY to INR 3,917 crore, with core EBITDA margin of 30%.
neutral
medium
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Biocon's Q4 FY24 group revenue from operations grew 4% YoY to INR 3,917 crore, with core EBITDA margin of 30%. Biosimilars revenue grew 12% YoY, driven by strong U.S. market share gains (Fulphila 21%, Ogivri 18%, Semglee 15%) and record emerging markets sales. Generics revenue declined 3% YoY due to API pricing pressure, but formulations grew 36% YoY. Syngene revenue fell 8% YoY due to research funding slowdown. Management expects FY25 to be a year of consolidation with back-ended growth, driven by new product launches in generics (liraglutide) and biosimilars (ustekinumab, aflibercept). Key risks include delayed U.S. adalimumab market opening, FDA inspection outcomes for Bengaluru and Malaysia facilities, and sustained API pricing headwinds.
बायोकॉन की चौथी तिमाही (Q4 FY24) की कुल आय पिछले साल से 4% बढ़कर 3,917 करोड़ रुपये हो गई। कंपनी का मुनाफा (EBITDA) 30% रहा। बायोसिमिलर दवाओं की बिक्री 12% बढ़ी, खासकर अमेरिका में फुलफिला (21%), ओगिवरी (18%) और सेमग्ली (15%) की हिस्सेदारी बढ़ने से। जेनेरिक दवाओं की बिक्री 3% घटी क्योंकि कच्चे माल (API) के दाम कम हुए, लेकिन फॉर्मूलेशन (तैयार दवाएं) 36% बढ़ीं। सिंजीन की आय 8% घटी क्योंकि रिसर्च फंडिंग कम हुई। कंपनी को FY25 में नई दवाओं (जैसे लिराग्लूटाइड, उस्टेकिनुमैब) से फायदा होने की उम्मीद है। जोखिम: अमेरिका में एडालिमुमैब बाजार में देरी, FDA जांच और API दामों पर दबाव।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Fulphila U.S. market share
21%
+7pp YoY
Biosimilar pegfilgrastim market share increased from 14% in March 2023 to 21%.
Ogivri U.S. market share
18%
+8pp YoY
Biosimilar trastuzumab market share increased from 10% in March 2023 to 18%.
Generics formulations growth
36%
+36% YoY
Formulations business grew 36% year-on-year, now 35% of product sales.
Biosimilars revenue (full year)
$1B+
+58% YoY
Biocon Biologics crossed $1 billion revenue for FY24, up 58% YoY.
What Changed vs Last Quarter
NEW
Syngene FY25 revenue growth: single-digit to low double-digit
Syngene expects constant currency revenue growth of single-digit to low double-digit in FY25.
NEW
Syngene FY25 EBITDA margin similar to FY24
Syngene expects operating EBITDA margin to be similar to FY24 levels (~31%).
NEW
Biosimilars R&D spend 8%-9% of revenues
Biocon Biologics expects R&D investments to be in the 8%-9% of revenues range.
NEW
Generics growth back-ended in FY25
Generics performance expected to build throughout the year with stronger second half, driven by new formulation launches.
DROPPED
BBL core EBITDA margin target of mid-30s
Management reiterated a mid-30s core EBITDA margin target for Biocon Biologics, with current margins depressed by ~5% due to integration-related one-off costs expected to normalize.
DROPPED
Generics business targeting mid-teens growth next fiscal
Generics business aims to return to mid-teens growth in FY25, driven by formulations momentum and new peptide revenues, despite current API pricing pressure.
DROPPED
Debt reduction focus with $200M repaid in Q3
Management emphasized continued debt reduction, having repaid $200M of acquisition debt in Q3, with further deleveraging expected from cash flows and other options.
DROPPED
Syngene facility operational in H2 FY25
The acquired Stelis biologics facility is expected to be operational in the second half of FY25, subject to regulatory approvals, adding 20,000L capacity.
NEW RISK
Debt reduction uncertainty
Management declined to provide specific quantitative guidance on debt reduction, raising concerns about pace and magnitude.
RISK GONE
High net debt and interest rate exposure
BBL net debt stands at $1.2B (excluding structured instruments), with floating-rate SOFR-linked debt exposing the company to high interest costs, which could pressure cash flows and R&D investment.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q2 FY24, Q3 FY24
The U.S. Adalimumab biosimilar market is expected to open meaningfully only in CY2025, delaying potential revenue contribution from this large opportunity.
Mentioned in Q1 FY24, Q2 FY24
Net debt to EBITDA elevated; interest costs rising due to high rate environment; deferred payments in FY25 may require additional funding.
Mentioned in Q1 FY24, Q2 FY24
Syngene is expected to deliver mid-teen constant currency growth for the full year, supported by strong performance in development and manufacturing services.
Fast read
Guidance and risk preview
Syngene expects constant currency revenue growth of single-digit to low double-digit in FY25.
Biosimilar adalimumab market in the U.S.
View Risks →